BlackRock and Nextech betting on radiopharma with ITM
ITM supplies Novartis with an agent for its Pluvicto radiopharmaceutical, which reached sales of $211m in the first quarter.
Nearly there!
A verification email is on its way to you. Please check your spam or junk folder just in case.
If you do not receive this within five minutes, please try to sign in again. If the problem persists, please email: subscriptions@pei.group .-
Sign in or Register
-
Issues with signing in? Click here
Don't have an account? Register now
-
